多西他赛联合表柔比星对局部晚期乳腺癌新辅助化疗的效果观察  

Effect Observation of Docetaxel Combined with Epirubicin on the Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

作　　者：陈金辉[1] 吴劲松[1] 蒋志斌[1] 

机构地区：[1]解放军白求恩国际和平医院普外二科,石家庄050082

出　　处：《解放军医药杂志》2013年第10期55-57,共3页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

摘　　要：目的探讨多西他赛(DOC)联合表柔比星(EPI)新辅助化疗局部晚期乳腺癌(LABC)的临床疗效、毒性反应和预后。方法选择2006年1月—2012年12月收治疗的LABC 89例,按化疗方案不同分为研究组46例和对照组43例,研究组应用DOC联合EPI新辅助化疗方案,对照组应用5-氟尿嘧啶(5-FU)联合EPI、环磷酰胺(CTX)化疗方案,观察临床疗效及毒性反应,治疗4个周期后3～4周行改良根治术。随访1年,评价预后。结果研究组部分缓解率和总有效率均较对照组高(P<0.05),而临床完全缓解率和病理完全缓解率以及毒副反应发生率与对照组比较差异均无统计学意义(P>0.05)。研究组1例,对照组2例因病情进展未能如期行改良根治术。随访1年,研究组远处转移率低于对照组,无瘤生存率高于对照组,差异均有统计学意义(P<0.05)。结论 DOC联合EPI新辅助化疗治疗晚期乳腺癌临床疗效显著,毒性反应较少,预后良好,是LABC新辅助化疗的优选方案。Objective To explore the clinical effect, side effects and prognosis of Docetaxel （DOC） combined with Epirubicin （EPI） in the neoadjuvant chemotherapy for locally advanced breast cancer （LABC）. Methods A total of 89 patients with LABC during January 2006 and December 2012 were divided into research group （n = 46） and control group （n = 43） based on different chemotherapies. The research group was treated with DOC combined with EPI, while control group received 5-Fluorouracil （5-FU） combined with EPI and Cyclophosphamide （CTX）. Curative effect and tox- ic reaction were observed, and reformative total correction was performed 3 - 4 weeks after 4 cycles of chemotherapy. The prognosis was evaluated after one year of follow-up. Results Compared with those in control group, in research group the partial remission and total effective rates were significantly higher （ P 〈 0.05 ） , while there were not significant differ- ences in clinical complete remission, pathologic complete remission rate and the incidence rate of adverse reaction be- tween the two groups （P 〉 0.05）. The reformative total correction was not performed because of developed pathogenetic condition for 1 patient in research group and 2 patients in control group. With one year of follow-up, the metastasis rate in research group was significantly lower than that in control group, while the disease free survival rate in research group was significantly higher than that in control group （ P 〈 0.05 ）. Conclusion The neoadjuvant chemotherapy of DOC combined with EPI in treatment of locally advanced breast cancer has advantages with better effect, less side effects and better prognosis, which is preferred as a neoadiuvant chemotherapy method.

关 键 词：多西他赛 表柔比星 抗肿瘤联合化疗方案 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤]